Results of the multivariate analyses of 328 patients in the current study compared with 211 patients in the prior SWOG study for similar patients
| . | Current study (SWOG-9333) . | Prior study (SWOG-9031)6-150 . |
|---|---|---|
| Lower complete remission rate | Secondary AML (P = .010) | Secondary AML (P = .0035) |
| Increasing age (P = .0025) | Unfavorable karyotype (P = .0031) | |
| MDR-1 + phenotype (P = .0041) | ||
| Higher resistant disease rate | CsA-inhibited Di(OC)2 efflux (P = .0012) | MDR-1 + phenotype (P = .0007) |
| Unfavorable karyotype (P = .017) | ||
| Shorter overall survival | Unfavorable karyotype (P = .0001) | Unfavorable karyotype (P < .0001) |
| Increasing age (P = .030) | Increasing age (P = .014) | |
| Increasing WBC count (P = .051) | Increasing WBC count (P = .029) | |
| Poorer performance status (P = .026) | ||
| Shorter relapse-free survival | High CD34 expression (P = .012) | Unfavorable karyotype (P = .028) |
| . | Current study (SWOG-9333) . | Prior study (SWOG-9031)6-150 . |
|---|---|---|
| Lower complete remission rate | Secondary AML (P = .010) | Secondary AML (P = .0035) |
| Increasing age (P = .0025) | Unfavorable karyotype (P = .0031) | |
| MDR-1 + phenotype (P = .0041) | ||
| Higher resistant disease rate | CsA-inhibited Di(OC)2 efflux (P = .0012) | MDR-1 + phenotype (P = .0007) |
| Unfavorable karyotype (P = .017) | ||
| Shorter overall survival | Unfavorable karyotype (P = .0001) | Unfavorable karyotype (P < .0001) |
| Increasing age (P = .030) | Increasing age (P = .014) | |
| Increasing WBC count (P = .051) | Increasing WBC count (P = .029) | |
| Poorer performance status (P = .026) | ||
| Shorter relapse-free survival | High CD34 expression (P = .012) | Unfavorable karyotype (P = .028) |
See Leith et al10 and Godwin et al16for details.